The enthusiasm for psychedelics in mental health treatment has overshadowed the need for robust evidence, with key research marred by bias and underreporting of risks.
In a year marked by setbacks, the FDA's rejection of the first MDMA therapy application highlights a growing concern about the integrity and reliability of psychedelic studies.
Collection
[
|
...
]